NT-proBNP Levels During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.

Change in Serum Levels of NT-proBNP During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06317428

Acronym

NTproBNP

Enrollment

Registered

2024-03-19

Start date

2022-06-28

Completion date

2025-12-31

Last updated

2024-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Keywords

COPD, Formoterol, glycopyrrolate, budesonide, NT-pro-BNP

Brief summary

Observational prospective study to evaluate serum NT-proBNP levels in a population of COPD patients three months after the iniation of triple inhaled formoterol/glycopyrrolate/budesonide therapy.

Detailed description

The purpose of the trixeo study is to conduct a prospective observational study to evaluate serum NT-proBNP levels in a population of COPD patients three months after the initiation of triple inhaled formoterol/glycopyrrolate/budesonide therapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* COPD; * Clinical indication for triple inhalation therapy with formoterol/glycopyrrolate/budesonide;

Exclusion criteria

* Life expectancy less than one year;

Design outcomes

Primary

Measure	Time frame	Description
Change in serum NT-pro-BNP levels	Before and 3 months after the start of triple therapy with formoterol/glycopyrrolate/budesonide	Before and 3 months after the introduction of bronchodilator therapy with formoterol/glycopyrrolate/budesonide, patients will be evaluated to assess serum NT-proBNP levels.

Countries

Italy

Contacts

Primary ContactAnna Rita Bonfigli

a.bonfigli@inrca.it0718003719

Outcome results